|
Kezar Life Sciences, Inc. (KZR) Évaluation DCF |
Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
Pré-Construits Pour Une Utilisation Rapide Et Efficace
Compatible MAC/PC, entièrement débloqué
Aucune Expertise N'Est Requise; Facile À Suivre
Kezar Life Sciences, Inc. (KZR) Bundle
Que vous soyez un investisseur ou un analyste, cette calculatrice DCF (KZR) est votre outil de référence pour une évaluation précise. Préchargé avec des données réelles de Kezar Life Sciences, Inc., vous pouvez ajuster les prévisions et observer les effets en temps réel.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | .0 | .0 | .0 | 7.0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Revenue Growth, % | 0 | 0 | 0 | 0 | -100 | -25 | -25 | -25 | -25 | -25 |
| EBITDA | -40.3 | -53.0 | -66.1 | -99.3 | -90.6 | .0 | .0 | .0 | .0 | .0 |
| EBITDA, % | 100 | 100 | 100 | -1417.91 | 100 | 60 | 60 | 60 | 60 | 60 |
| Depreciation | 1.5 | 1.5 | 1.0 | 1.1 | -5.3 | .0 | .0 | .0 | .0 | .0 |
| Depreciation, % | 100 | 100 | 100 | 15.23 | 100 | 83.05 | 83.05 | 83.05 | 83.05 | 83.05 |
| EBIT | -41.8 | -54.5 | -67.1 | -100.3 | -85.3 | .0 | .0 | .0 | .0 | .0 |
| EBIT, % | 100 | 100 | 100 | -1433.14 | 100 | 60 | 60 | 60 | 60 | 60 |
| Total Cash | 140.4 | 208.4 | 276.6 | 201.4 | 132.2 | .0 | .0 | .0 | .0 | .0 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables, % | 100 | 100 | 100 | 0 | 100 | 80 | 80 | 80 | 80 | 80 |
| Inventories | 2.0 | 2.5 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Inventories, % | 100 | 100 | 100 | 0 | 100 | 80 | 80 | 80 | 80 | 80 |
| Accounts Payable | 2.4 | 2.0 | 2.5 | 8.3 | 3.7 | .0 | .0 | .0 | .0 | .0 |
| Accounts Payable, % | 100 | 100 | 100 | 117.87 | 100 | 100 | 100 | 100 | 100 | 100 |
| Capital Expenditure | -.2 | -.3 | -1.6 | -1.8 | .0 | .0 | .0 | .0 | .0 | .0 |
| Capital Expenditure, % | 100 | 100 | 100 | -25.86 | 100 | -5.17 | -5.17 | -5.17 | -5.17 | -5.17 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -39.0 | -53.1 | -64.3 | -100.3 | -85.3 | .0 | .0 | .0 | .0 | .0 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -37.3 | -52.8 | -61.9 | -95.3 | -95.2 | -3.7 | .0 | .0 | .0 | .0 |
| WACC, % | 6.91 | 6.91 | 6.91 | 6.92 | 6.92 | 6.91 | 6.91 | 6.91 | 6.91 | 6.91 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -3.4 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 0 | |||||||||
| Terminal Value | 0 | |||||||||
| Present Terminal Value | 0 | |||||||||
| Enterprise Value | -3 | |||||||||
| Net Debt | -31 | |||||||||
| Equity Value | 27 | |||||||||
| Diluted Shares Outstanding, MM | 73 | |||||||||
| Equity Value Per Share | 0.37 |
What You Will Get
- Real Kezar Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Kezar Life Sciences, Inc. (KZR).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates to fit your analysis.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Kezar's fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections specific to Kezar Life Sciences, Inc. (KZR).
- Time-Saving and Accurate: Skip building models from scratch while ensuring precision and flexibility in your financial assessments.
Key Features
- Comprehensive Financial Data: Gain access to precise historical data and future forecasts for Kezar Life Sciences, Inc. (KZR).
- Adjustable Forecast Parameters: Modify highlighted cells for key metrics like WACC, growth rates, and profit margins.
- Real-Time Calculations: Instant updates for DCF, Net Present Value (NPV), and cash flow analysis.
- User-Friendly Dashboard: Intuitive charts and summaries to help visualize your valuation outcomes.
- Designed for All Skill Levels: An easy-to-navigate framework suitable for investors, CFOs, and consultants alike.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Kezar Life Sciences' pre-filled financial data and projections.
- Step 3: Adjust key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you modify assumptions.
- Step 5: Evaluate the outputs and leverage the results for your investment strategies.
Why Choose This Calculator for Kezar Life Sciences, Inc. (KZR)?
- Accuracy: Utilizes real Kezar financial data for precise calculations.
- Flexibility: Allows users to easily adjust and test various input parameters.
- Time-Saving: Eliminate the need to create a DCF model from the ground up.
- Professional-Grade: Crafted with the precision and usability expected by industry leaders.
- User-Friendly: Intuitive interface suitable for users with varying levels of financial expertise.
Who Should Use This Product?
- Professional Investors: Create comprehensive and accurate valuation models for portfolio assessment of Kezar Life Sciences, Inc. (KZR).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Advisors: Deliver precise valuation insights to clients regarding Kezar Life Sciences, Inc. (KZR) stock.
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how biotech companies like Kezar Life Sciences, Inc. (KZR) are valued in the marketplace.
What the Template Contains
- Historical Data: Includes Kezar Life Sciences’ past financials and baseline forecasts.
- DCF and Levered DCF Models: Detailed templates to calculate Kezar Life Sciences’ intrinsic value.
- WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
- Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
- Quarterly and Annual Statements: A complete breakdown of Kezar Life Sciences’ financials.
- Interactive Dashboard: Visualize valuation results and projections dynamically.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.